Terms: = Breast cancer AND DDX6, P54, 1656, ENSG00000110367, HLR2, P26196, RCK, FLJ36338 AND Treatment
11 results:
1. VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
[TBL] [Abstract] [Full Text] [Related]
2. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T; Niikura N; Watanabe K; Takeshita T; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2024 Jan; 203(2):225-234. PubMed ID: 37875670
[TBL] [Abstract] [Full Text] [Related]
3. Isolated Tumor Cells in Sentinel Lymph Nodes of Primary Invasive breast Carcinoma: A Cohort Analysis.
Bethune GC; Karkada MA; DeCoste R; Barnes PJ; Rayson D
Clin Breast Cancer; 2019 Aug; 19(4):286-291. PubMed ID: 31078418
[TBL] [Abstract] [Full Text] [Related]
4. Study on the expression of PAK4 and p54 protein in breast cancer.
Bi Y; Tian M; Le J; Wang L; Liu X; Qu J; Hao M
World J Surg Oncol; 2016 Jun; 14(1):160. PubMed ID: 27297086
[TBL] [Abstract] [Full Text] [Related]
5. Transforming growth factor-β1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion.
Wang Y; Lui WY
Eur J Cancer; 2012 Dec; 48(18):3475-87. PubMed ID: 22647687
[TBL] [Abstract] [Full Text] [Related]
6. The nitric oxide pathway: is L-arginine a gate to the new millennium medicine? A meta-analysis of L-arginine effects.
Fisman EZ; Tenenbaum A; Shapira I; Pines A; Motro M
J Med; 1999; 30(3-4):131-48. PubMed ID: 17312667
[TBL] [Abstract] [Full Text] [Related]
7. Interaction of the progesterone receptor with binding proteins for FK506 and cyclosporin A.
Milad M; Sullivan W; Diehl E; Altmann M; Nordeen S; Edwards DP; Toft DO
Mol Endocrinol; 1995 Jul; 9(7):838-47. PubMed ID: 7476967
[TBL] [Abstract] [Full Text] [Related]
8. Needle localization for nonpalpable breast lesions.
Sailors DM; Crabtree JD; Land RL; Rose WB; Burns RP; Barker DE
Am Surg; 1994 Mar; 60(3):186-9. PubMed ID: 8116978
[TBL] [Abstract] [Full Text] [Related]
9. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
[TBL] [Abstract] [Full Text] [Related]
10. [Elective radiotherapy in breast carcinoma].
Nervi C; Arcangeli G; Tirindelli Danesi D; Creton G
Tumori; 1982 Feb; 68(1):73-80. PubMed ID: 7071949
[TBL] [Abstract] [Full Text] [Related]
11. Tamoxifen in disseminated breast cancer.
Ferrazzi E; Cartei G; De Besi P; Fornasiero A; Palù G; Paccagnella A; Sperandio P; Fosser V; Grigoletto E; Fiorentino M
Tumori; 1977; 63(5):463-8. PubMed ID: 601876
[TBL] [Abstract] [Full Text] [Related]
